HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.
about
P1343
BKM120 induces apoptosis and inhibits tumor growth in medulloblastomaInvestigation of brain tissue infiltration by medulloblastoma cells in an ex vivo modelTargeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma.MB3W1 is an orthotopic xenograft model for anaplastic medulloblastoma displaying cancer stem cell- and Group 3-propertiesMolecular profiling of childhood cancer: Biomarkers and novel therapiesHDAC and PI3K Antagonists Cooperate to Inhibit Growth of MYC-Driven Medulloblastoma.Risk stratification of childhood medulloblastoma in the molecular era: the current consensus.Role of MYC in Medulloblastoma.BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.Active medulloblastoma enhancers reveal subgroup-specific cellular origins.Molecular Classification of Medulloblastoma.The role of chromatin remodeling in medulloblastoma.The biologic era of childhood medulloblastoma and clues to novel therapies.Targeting of histone deacetylases in brain tumors.Medulloblastoma development: tumor biology informs treatment decisionsTargeted approaches to childhood cancer: progress in drug discovery and development.Evolving molecular era of childhood medulloblastoma: time to revisit therapy.An epigenetic gateway to brain tumor cell identity.Pediatric brain tumor cell lines.Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing.Modeling and Targeting MYC Genes in Childhood Brain Tumors.Panobinostat, a histone deacetylase inhibitor, suppresses leptomeningeal seeding in a medulloblastoma animal model.Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors.Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors.Using droplet digital PCR to analyze MYCN and ALK copy number in plasma from patients with neuroblastoma.Characterization of a novel OTX2-driven stem cell program in Group 3 and Group 4 medulloblastoma.Epigenetic regulation in medulloblastoma.Advances in Genomics Explain Medulloblastoma Behavior at the Bedside.Mouse medulloblastoma driven by CRISPR activation of cellular Myc.
P2860
Q33853264-3E60620A-01C7-49EC-93DE-D15A9D90D55DQ33903199-19A1995E-E1B5-402A-BB56-7C681212DD52Q35246513-138C4675-CCAE-4BF7-91B1-6399CE92D89AQ35925281-E93CA03B-B73C-4F4D-BE8F-AAD26EE45137Q36250783-CFD646F2-EEED-490D-88B3-4B32D9EE8522Q36694288-E463A990-FB3C-4E6F-ABD0-BECD0F141EB5Q36901551-BC95CF01-C2AB-4802-8549-FEA2C3673EB1Q37256443-5F59702B-0359-4E8F-BD8E-01F194F3DF68Q37420196-F4832195-B093-418D-9107-8A61EBB2F81BQ37517791-2D49B253-B4DB-4840-A4E8-BC958BB42C20Q37573700-620B70D8-C869-44DB-8BCA-AB7A41790121Q38083796-BD42C073-07C9-4626-8D2F-2195F5F87182Q38206276-E816CBA1-A32F-4D9D-87D4-587584BD00C9Q38233117-9BB0975C-364F-4EF6-B232-1E43B33C36D2Q38376606-2967A606-2437-4FEF-85DB-98593880ADB0Q38404462-3214A6E4-22E9-4C72-B5C4-A6537297984DQ38652681-16AFFAEF-456D-481E-9EC8-71A7124AE5AFQ38682159-2FC0967A-108D-4C09-9BA5-E9A74FD39722Q38957473-1A1255F8-5925-40CA-A708-28C854861915Q38993103-F7C9147E-2322-4105-92DD-D1ABDFF9E9E4Q39195507-1F99B4D3-D1C0-424F-95C2-927A064FA85FQ41344917-5EBA06DF-E67E-48B3-8E8D-2EFFE54072E6Q46062200-9A6D33A9-6174-4F6A-998A-1C794E33D136Q47370033-44BC63CB-5C3F-4ED6-B150-C5640E8E7F7CQ47442252-84071042-080E-49AB-A540-7F03742BA030Q47551116-309E16D9-22A0-48F7-B14E-52A9EB632471Q47900778-DD992FF8-013E-4539-9823-141766BCD1A1Q48116800-77107057-3011-485D-BBAE-D7D232034169Q55261643-CC0E546C-C475-4C8C-813E-6112DFA987A4
P2860
HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
HD-MB03 is a novel Group 3 med ...... acetylase inhibitor treatment.
@en
HD-MB03 is a novel Group 3 med ...... acetylase inhibitor treatment.
@nl
type
label
HD-MB03 is a novel Group 3 med ...... acetylase inhibitor treatment.
@en
HD-MB03 is a novel Group 3 med ...... acetylase inhibitor treatment.
@nl
prefLabel
HD-MB03 is a novel Group 3 med ...... acetylase inhibitor treatment.
@en
HD-MB03 is a novel Group 3 med ...... acetylase inhibitor treatment.
@nl
P2093
P2860
P50
P1476
HD-MB03 is a novel Group 3 med ...... eacetylase inhibitor treatment
@en
P2093
Andreas E Kulozik
Andrey Korshunov
Arnulf Pekrun
Hedwig E Deubzer
Larissa Savelyeva
Lena M Brueckner
Marcel Kool
Marco Lodrini
P2860
P2888
P304
P356
10.1007/S11060-012-0978-1
P4510
P577
2012-10-06T00:00:00Z